C80 D90
Conditions
Interventions
Group 1: As part of the intervention, our EVO card is given to the patients. This is an information for the family doctor, which vaccinations must be supplemented as part of the antineoplastic therapy
Sponsors
Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Written informed consent - Age >/= 18 years - Established cancer diagnosis - Baseline: Under anti-neoplastic treatment - Follow-up: Under anti-neoplastic treatment with at least one doctor appointment at study side at least 4 weeks before - Intervention: Planned or under anti-neoplastic treatment
Exclusion criteria
Exclusion criteria: - Patients who are unable to consent - Known intolerance towards planned vaccinations - B- and T-cell depleting treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective of this trial is to assess the effectiveness of implementing the EVO card in the workflow of hematological-oncological outpatient clinics in increasing vaccination rates for Streptococcus pneumoniae in patients under antineoplastic treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives are - evaluation of the effectiveness of implementing the EVO card in the workflow of haematological-oncological outpatient clinics and associated increasing vaccination rates für Hepatitis B, Herpes Zoster and Influenza in patients under antineoplastic treatment - Pre-interventional vaccination rates - analyzation of the effectiveness of vaccination in relation to time and sort of antineoplastic treatment and underlying illness - vaccination tolerances - acceptance of the EVO-card by the medical staff | — |
Countries
Germany
Contacts
Public ContactTil Kiderlen
Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin
Outcome results
None listed